What is LGND's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 6.05B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for LGND?

P/E (TTM) is 31.31 and 52-week range is $175.89 to $326.63 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s LGND figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for LGND?

The company profile lists revenue (TTM) near $267M, net income (TTM) near $181M, EPS (TTM) near $9.40 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Ligand Pharmaceuticals Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Jupiter, Florida, US, 20M shares outstanding, ISIN US53220K5048 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Ligand Pharmaceuticals Inc

$LGND

Health Care · Pharmaceuticals

IR Run Scenarios

$303.53

-2.44%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company that involves clinical development and commercialization of high-value medicines. The company is headquartered in Jupiter, Florida and currently employs 47 full-time employees. The company does this by financing, licensing its technologies or both. The company operates two infrastructure-light royalty-generating IP platform technologies. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled FDA-approved products, including Gilead’s Veklury, Amgen’s Kyprolis, Baxter’s Nexterone, and Acrotech Biopharma’s Evomela. Its NITRICIL platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a range of indications. Its technologies also include HepDirect, LTP and BEPro Technology Platform, and Pelican Expression Technology. The company has multiple alliances, licenses and other business relationships with various pharmaceutical companies.

Employees

Website

www.ligand.com/

IPO

1992-11-18

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)